JP2012509289A - ヘパラン硫酸の精製方法並びに美容用及び皮膚用調製物中におけるその使用 - Google Patents
ヘパラン硫酸の精製方法並びに美容用及び皮膚用調製物中におけるその使用 Download PDFInfo
- Publication number
- JP2012509289A JP2012509289A JP2011536799A JP2011536799A JP2012509289A JP 2012509289 A JP2012509289 A JP 2012509289A JP 2011536799 A JP2011536799 A JP 2011536799A JP 2011536799 A JP2011536799 A JP 2011536799A JP 2012509289 A JP2012509289 A JP 2012509289A
- Authority
- JP
- Japan
- Prior art keywords
- heparan sulfate
- cosmetic
- composition according
- comprised
- salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920002971 Heparan sulfate Polymers 0.000 title abstract description 47
- 239000002537 cosmetic Substances 0.000 title abstract description 21
- 238000000034 method Methods 0.000 title abstract description 9
- 238000000746 purification Methods 0.000 title description 5
- 238000002360 preparation method Methods 0.000 title description 4
- 239000000203 mixture Substances 0.000 abstract description 17
- 229920005989 resin Polymers 0.000 abstract description 11
- 239000011347 resin Substances 0.000 abstract description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 10
- 230000000202 analgesic effect Effects 0.000 abstract description 7
- 230000003712 anti-aging effect Effects 0.000 abstract description 7
- 230000002087 whitening effect Effects 0.000 abstract description 7
- 239000003957 anion exchange resin Substances 0.000 abstract description 5
- 238000003795 desorption Methods 0.000 abstract description 5
- 238000001179 sorption measurement Methods 0.000 abstract description 4
- 230000007928 solubilization Effects 0.000 abstract description 2
- 238000005063 solubilization Methods 0.000 abstract description 2
- 239000000758 substrate Substances 0.000 description 24
- 230000000694 effects Effects 0.000 description 16
- 238000012360 testing method Methods 0.000 description 16
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 15
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 12
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 10
- 238000000338 in vitro Methods 0.000 description 9
- 239000013642 negative control Substances 0.000 description 9
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 8
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 8
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 8
- 206010015150 Erythema Diseases 0.000 description 7
- 231100000321 erythema Toxicity 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- 239000000839 emulsion Substances 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- 235000002639 sodium chloride Nutrition 0.000 description 6
- 238000010998 test method Methods 0.000 description 6
- 102000016611 Proteoglycans Human genes 0.000 description 5
- 108010067787 Proteoglycans Proteins 0.000 description 5
- 239000003963 antioxidant agent Substances 0.000 description 5
- 230000003078 antioxidant effect Effects 0.000 description 5
- 235000006708 antioxidants Nutrition 0.000 description 5
- 210000002950 fibroblast Anatomy 0.000 description 5
- 229940068196 placebo Drugs 0.000 description 5
- 239000000902 placebo Substances 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 238000001243 protein synthesis Methods 0.000 description 5
- 230000014616 translation Effects 0.000 description 5
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 4
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 4
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 4
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- OQILCOQZDHPEAZ-UHFFFAOYSA-N Palmitinsaeure-octylester Natural products CCCCCCCCCCCCCCCC(=O)OCCCCCCCC OQILCOQZDHPEAZ-UHFFFAOYSA-N 0.000 description 4
- 229920002125 Sokalan® Polymers 0.000 description 4
- 125000005250 alkyl acrylate group Chemical group 0.000 description 4
- 210000003651 basophil Anatomy 0.000 description 4
- 229960001631 carbomer Drugs 0.000 description 4
- 230000004663 cell proliferation Effects 0.000 description 4
- 229920001429 chelating resin Polymers 0.000 description 4
- 229920006037 cross link polymer Polymers 0.000 description 4
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 4
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 4
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 4
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 4
- GJQLBGWSDGMZKM-UHFFFAOYSA-N ethylhexyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(CC)CCCCC GJQLBGWSDGMZKM-UHFFFAOYSA-N 0.000 description 4
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 4
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 4
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 4
- 229960002216 methylparaben Drugs 0.000 description 4
- 229960005323 phenoxyethanol Drugs 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 4
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 4
- 229960004063 propylene glycol Drugs 0.000 description 4
- 235000013772 propylene glycol Nutrition 0.000 description 4
- 229960003415 propylparaben Drugs 0.000 description 4
- 239000003642 reactive oxygen metabolite Substances 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 3
- 229930003268 Vitamin C Natural products 0.000 description 3
- 230000036576 dermal application Effects 0.000 description 3
- 230000008030 elimination Effects 0.000 description 3
- 238000003379 elimination reaction Methods 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 235000019154 vitamin C Nutrition 0.000 description 3
- 239000011718 vitamin C Substances 0.000 description 3
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 102000016942 Elastin Human genes 0.000 description 2
- 108010014258 Elastin Proteins 0.000 description 2
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 2
- 101800003838 Epidermal growth factor Proteins 0.000 description 2
- 229920002683 Glycosaminoglycan Polymers 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 125000000129 anionic group Chemical group 0.000 description 2
- 230000001153 anti-wrinkle effect Effects 0.000 description 2
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 210000004207 dermis Anatomy 0.000 description 2
- 229920002549 elastin Polymers 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 229940116977 epidermal growth factor Drugs 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 229960002442 glucosamine Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 210000004347 intestinal mucosa Anatomy 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 230000036573 scar formation Effects 0.000 description 2
- 210000004927 skin cell Anatomy 0.000 description 2
- 229940083608 sodium hydroxide Drugs 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 229920001499 Heparinoid Polymers 0.000 description 1
- 241000208125 Nicotiana Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 230000037338 UVA radiation Effects 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- -1 alkaline earth metal salt Chemical class 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000002744 anti-aggregatory effect Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 238000004061 bleaching Methods 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000010307 cell transformation Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000013058 crude material Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 210000001061 forehead Anatomy 0.000 description 1
- 239000002554 heparinoid Substances 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- UEGPKNKPLBYCNK-UHFFFAOYSA-L magnesium acetate Chemical compound [Mg+2].CC([O-])=O.CC([O-])=O UEGPKNKPLBYCNK-UHFFFAOYSA-L 0.000 description 1
- 235000011147 magnesium chloride Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000036564 melanin content Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 125000001741 organic sulfur group Chemical group 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 231100000719 pollutant Toxicity 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 239000012508 resin bead Substances 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/727—Heparin; Heparan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/004—Aftersun preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
- A61K2800/522—Antioxidants; Radical scavengers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/75—Anti-irritant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Dermatology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Birds (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Cosmetics (AREA)
- Medicinal Preparation (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08169547.0 | 2008-11-20 | ||
| EP08169547 | 2008-11-20 | ||
| PCT/EP2009/062582 WO2010057710A2 (en) | 2008-11-20 | 2009-09-29 | Process for the purification of heparan sulfate and use thereof in cosmetological and dermatological preparations |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014117306A Division JP6058588B2 (ja) | 2008-11-20 | 2014-06-06 | ヘパラン硫酸の精製方法並びに美容用及び皮膚用調製物中におけるその使用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2012509289A true JP2012509289A (ja) | 2012-04-19 |
Family
ID=41587870
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011536799A Pending JP2012509289A (ja) | 2008-11-20 | 2009-09-29 | ヘパラン硫酸の精製方法並びに美容用及び皮膚用調製物中におけるその使用 |
| JP2014117306A Expired - Fee Related JP6058588B2 (ja) | 2008-11-20 | 2014-06-06 | ヘパラン硫酸の精製方法並びに美容用及び皮膚用調製物中におけるその使用 |
| JP2016235665A Pending JP2017043638A (ja) | 2008-11-20 | 2016-12-05 | ヘパラン硫酸の精製方法並びに美容用及び皮膚用調製物中におけるその使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014117306A Expired - Fee Related JP6058588B2 (ja) | 2008-11-20 | 2014-06-06 | ヘパラン硫酸の精製方法並びに美容用及び皮膚用調製物中におけるその使用 |
| JP2016235665A Pending JP2017043638A (ja) | 2008-11-20 | 2016-12-05 | ヘパラン硫酸の精製方法並びに美容用及び皮膚用調製物中におけるその使用 |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US9440099B2 (enExample) |
| EP (2) | EP2346573B1 (enExample) |
| JP (3) | JP2012509289A (enExample) |
| KR (1) | KR101669528B1 (enExample) |
| DK (2) | DK2346573T3 (enExample) |
| ES (2) | ES2507495T3 (enExample) |
| HR (2) | HRP20140862T1 (enExample) |
| HU (1) | HUE035362T2 (enExample) |
| LT (1) | LT2679278T (enExample) |
| NO (1) | NO2679278T3 (enExample) |
| PL (2) | PL2679278T3 (enExample) |
| PT (2) | PT2679278T (enExample) |
| SI (2) | SI2346573T1 (enExample) |
| WO (1) | WO2010057710A2 (enExample) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2016503781A (ja) * | 2012-12-21 | 2016-02-08 | ロレアル | 皮膚を色素除去するための、ｃ−キシロシド化合物、その組成物及びその使用 |
| CN108329405A (zh) * | 2018-02-08 | 2018-07-27 | 黄石市典雅生物科技有限公司 | 一种树脂吸附状态下保护及纯化肝素钠的方法 |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2012509289A (ja) * | 2008-11-20 | 2012-04-19 | ラボラトリ・デリバティ・オルガニシ・エス・ピー・エイ | ヘパラン硫酸の精製方法並びに美容用及び皮膚用調製物中におけるその使用 |
| EP2997047B1 (en) | 2013-05-16 | 2021-04-28 | Agency For Science, Technology And Research | Heparan sulphates |
| SG11201704086WA (en) * | 2014-11-19 | 2017-06-29 | Agency Science Tech & Res | Cosmetic use of heparan sulphate |
| CN107249599A (zh) | 2014-11-19 | 2017-10-13 | 新加坡科技研究局 | 硫酸乙酰肝素用于皮肤修复和/或再生 |
| ITUB20160156A1 (it) * | 2016-02-05 | 2017-08-05 | Laboratori Derivati Organici Spa | Composizioni comprendenti una miscela di glicosamminoglicani e loro uso in composizioni cosmetiche e dermatologiche |
| CN111909288B (zh) * | 2020-08-13 | 2021-09-03 | 山东辰龙药业有限公司 | 一种肝素钠的精制方法 |
| KR20220096932A (ko) | 2020-12-31 | 2022-07-07 | 주식회사 유연테크 | 분진제거와 제습기능이 결합된 제습 싸이크론 건조기 |
| EP4580751A2 (en) * | 2022-09-29 | 2025-07-09 | Adora Animal Health Corporation | Storage stable formulations of sulfated glycosaminoglycans and fragments derived therefrom for the treatment of pain and other medical conditions |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS63150209A (ja) * | 1986-12-15 | 1988-06-22 | Kanebo Ltd | 皮膚化粧料 |
| JPS6422809A (en) * | 1987-07-15 | 1989-01-25 | Kanebo Ltd | Skin cosmetic |
| JPS6422812A (en) * | 1987-07-15 | 1989-01-25 | Kanebo Ltd | Skin cosmetic |
| JPH04187613A (ja) * | 1990-11-22 | 1992-07-06 | Pola Chem Ind Inc | 皮膚化粧料 |
| JPH05310548A (ja) * | 1992-05-13 | 1993-11-22 | Taisho Pharmaceut Co Ltd | 皮膚外用剤 |
| JPH0899861A (ja) * | 1994-09-30 | 1996-04-16 | Kose Corp | 皮膚外用剤 |
| JP2003171256A (ja) * | 2001-12-03 | 2003-06-17 | Nonogawa Shoji Kk | 皮膚外用剤 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1212143B (it) * | 1987-06-26 | 1989-11-08 | Crinos Industria Farmaco | Composizione ad attivita'tricogena. |
| DK505488D0 (da) * | 1987-12-21 | 1988-09-09 | Bar Shalom Daniel | Middel og anvendelse af samme |
| FR2643909B1 (fr) * | 1989-03-03 | 1993-01-22 | Bioetica Sa | Composition de base pour la preparation d'une composition cosmetique formant composition capillaire et composition cosmetique formant composition capillaire ainsi preparee, contenant de l'heparine ou de l'heparane sulfate |
| JPH03161416A (ja) * | 1989-11-21 | 1991-07-11 | Kanebo Ltd | 皮膚化粧料 |
| GB9318288D0 (en) * | 1993-09-03 | 1993-10-20 | Nycomed Imaging As | Improvements in or relating to contrast agents |
| SE9402531L (sv) * | 1994-07-19 | 1996-01-20 | Medicarb Ab | Sårläkningsmedel |
| US5989874A (en) * | 1995-03-27 | 1999-11-23 | Tayca Corporation | Humectant, antistatic agent, dispersant and film-forming agent having polysaccharide as active principle, preparation process of polysaccharides, and Kliebsiella ocytoca TNM-3 strain |
| CN1196734A (zh) * | 1995-09-19 | 1998-10-21 | 生化学工业株式会社 | 消炎药 |
| US5935599A (en) * | 1996-10-28 | 1999-08-10 | The Board Of Trustees Of The University Of Illinois | Polymer-associated liposomes for drug delivery and method of manufacturing the same |
| JP3687277B2 (ja) * | 1997-06-10 | 2005-08-24 | サンスター株式会社 | 美白化粧料 |
| GB9913237D0 (en) * | 1999-06-08 | 1999-08-04 | K C L Enterprises Limited | Product |
| JP4754066B2 (ja) * | 2000-12-22 | 2011-08-24 | 株式会社林原生物化学研究所 | 抗関節障害剤 |
| DE10161149B4 (de) * | 2001-12-12 | 2007-03-08 | Ursapharm Arzneimittel Gmbh & Co. Kg | Verwendung von Heparin-haltigem Ophthalmikum |
| US20070129430A1 (en) * | 2003-10-07 | 2007-06-07 | Satomi Miyata | Agent for enhancing the production of collagen, their preparation and use |
| DE102004036689A1 (de) * | 2004-07-28 | 2006-03-23 | Henkel Kgaa | Rückstandsarmer Deodorant- oder Antitranspirant-Stift auf Basis einer Öl-in-Wasser-Dispersion |
| JP4975751B2 (ja) * | 2005-10-13 | 2012-07-11 | グ、ジェニファー、エル． | ミネラル・コラーゲン・キレートおよびその製造方法と使用方法 |
| JP2007254316A (ja) * | 2006-03-22 | 2007-10-04 | Seikagaku Kogyo Co Ltd | Ｈａマトリックス形成阻害剤 |
| JP4564471B2 (ja) * | 2006-07-06 | 2010-10-20 | 株式会社コーセー | 外用に適する組成物 |
| ITMI20072237A1 (it) * | 2007-11-27 | 2009-05-28 | Sigea Srl | Esteri misti butirrico-formico di polisaccaridi acidi, loro preparazione ed uso come dermocosmetici |
| JP2012509289A (ja) * | 2008-11-20 | 2012-04-19 | ラボラトリ・デリバティ・オルガニシ・エス・ピー・エイ | ヘパラン硫酸の精製方法並びに美容用及び皮膚用調製物中におけるその使用 |
-
2009
- 2009-09-29 JP JP2011536799A patent/JP2012509289A/ja active Pending
- 2009-09-29 ES ES09783522.7T patent/ES2507495T3/es active Active
- 2009-09-29 DK DK09783522.7T patent/DK2346573T3/da active
- 2009-09-29 PL PL13159487T patent/PL2679278T3/pl unknown
- 2009-09-29 LT LTEP13159487.1T patent/LT2679278T/lt unknown
- 2009-09-29 EP EP09783522.7A patent/EP2346573B1/en active Active
- 2009-09-29 US US13/129,030 patent/US9440099B2/en active Active
- 2009-09-29 WO PCT/EP2009/062582 patent/WO2010057710A2/en not_active Ceased
- 2009-09-29 HR HRP20140862AT patent/HRP20140862T1/hr unknown
- 2009-09-29 NO NO13159487A patent/NO2679278T3/no unknown
- 2009-09-29 EP EP13159487.1A patent/EP2679278B1/en active Active
- 2009-09-29 SI SI200931013T patent/SI2346573T1/sl unknown
- 2009-09-29 PL PL09783522T patent/PL2346573T3/pl unknown
- 2009-09-29 KR KR1020117013681A patent/KR101669528B1/ko active Active
- 2009-09-29 SI SI200931764T patent/SI2679278T1/en unknown
- 2009-09-29 HU HUE13159487A patent/HUE035362T2/en unknown
- 2009-09-29 DK DK13159487.1T patent/DK2679278T3/en active
- 2009-09-29 PT PT131594871T patent/PT2679278T/pt unknown
- 2009-09-29 PT PT97835227T patent/PT2346573E/pt unknown
- 2009-09-29 ES ES13159487.1T patent/ES2650937T3/es active Active
-
2014
- 2014-06-06 JP JP2014117306A patent/JP6058588B2/ja not_active Expired - Fee Related
-
2016
- 2016-08-04 US US15/228,150 patent/US20160338935A1/en not_active Abandoned
- 2016-12-05 JP JP2016235665A patent/JP2017043638A/ja active Pending
-
2017
- 2017-10-02 US US15/722,448 patent/US20180028427A1/en not_active Abandoned
- 2017-11-29 HR HRP20171861TT patent/HRP20171861T1/hr unknown
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS63150209A (ja) * | 1986-12-15 | 1988-06-22 | Kanebo Ltd | 皮膚化粧料 |
| JPS6422809A (en) * | 1987-07-15 | 1989-01-25 | Kanebo Ltd | Skin cosmetic |
| JPS6422812A (en) * | 1987-07-15 | 1989-01-25 | Kanebo Ltd | Skin cosmetic |
| JPH04187613A (ja) * | 1990-11-22 | 1992-07-06 | Pola Chem Ind Inc | 皮膚化粧料 |
| JPH05310548A (ja) * | 1992-05-13 | 1993-11-22 | Taisho Pharmaceut Co Ltd | 皮膚外用剤 |
| JPH0899861A (ja) * | 1994-09-30 | 1996-04-16 | Kose Corp | 皮膚外用剤 |
| JP2003171256A (ja) * | 2001-12-03 | 2003-06-17 | Nonogawa Shoji Kk | 皮膚外用剤 |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2016503781A (ja) * | 2012-12-21 | 2016-02-08 | ロレアル | 皮膚を色素除去するための、ｃ−キシロシド化合物、その組成物及びその使用 |
| CN108329405A (zh) * | 2018-02-08 | 2018-07-27 | 黄石市典雅生物科技有限公司 | 一种树脂吸附状态下保护及纯化肝素钠的方法 |
| CN108329405B (zh) * | 2018-02-08 | 2020-06-23 | 黄石市典雅生物科技有限公司 | 一种树脂吸附状态下保护及纯化肝素钠的方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| PL2346573T3 (pl) | 2014-12-31 |
| HUE035362T2 (en) | 2018-05-02 |
| PT2346573E (pt) | 2014-09-25 |
| HRP20171861T1 (hr) | 2018-01-26 |
| JP2014159488A (ja) | 2014-09-04 |
| KR101669528B1 (ko) | 2016-10-26 |
| EP2346573A2 (en) | 2011-07-27 |
| US20180028427A1 (en) | 2018-02-01 |
| US20110288047A1 (en) | 2011-11-24 |
| ES2507495T3 (es) | 2014-10-15 |
| KR20110086734A (ko) | 2011-07-29 |
| US20160338935A1 (en) | 2016-11-24 |
| EP2346573B1 (en) | 2014-06-25 |
| WO2010057710A2 (en) | 2010-05-27 |
| US9440099B2 (en) | 2016-09-13 |
| PT2679278T (pt) | 2017-12-13 |
| ES2650937T3 (es) | 2018-01-23 |
| LT2679278T (lt) | 2017-12-27 |
| WO2010057710A9 (en) | 2011-08-18 |
| PL2679278T3 (pl) | 2018-02-28 |
| HRP20140862T1 (hr) | 2014-11-07 |
| EP2679278A1 (en) | 2014-01-01 |
| EP2679278B1 (en) | 2017-09-06 |
| DK2346573T3 (da) | 2014-10-06 |
| JP6058588B2 (ja) | 2017-01-11 |
| JP2017043638A (ja) | 2017-03-02 |
| WO2010057710A3 (en) | 2011-06-03 |
| SI2346573T1 (sl) | 2014-10-30 |
| NO2679278T3 (enExample) | 2018-02-03 |
| DK2679278T3 (en) | 2017-12-11 |
| SI2679278T1 (en) | 2018-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6058588B2 (ja) | ヘパラン硫酸の精製方法並びに美容用及び皮膚用調製物中におけるその使用 | |
| JP2014159488A5 (enExample) | ||
| CA2703532C (en) | Topically administered, skin-penetrating glycosaminoglycan formulations suitable for use in cosmetic and pharmaceutical applications | |
| JP6000511B2 (ja) | 酸性多糖の酪酸−ギ酸混合エステル、ならびに肌用化粧品としてのその調製および使用 | |
| JP2012241192A (ja) | ヒアルロン酸エステル、それらの製造および皮膚科学における使用 | |
| CN113527537A (zh) | 一种左旋维生素c透明质酸酯衍生物及其制备方法和应用 | |
| TW201414478A (zh) | 經修飾的透明質酸衍生物及其用途 | |
| JP3342007B2 (ja) | 低分子ヘパリン修飾体及び皮膚潰瘍治療剤 | |
| JP2015507070A (ja) | 部分的に解重合したグリコサミノグリカン銀及び金塩 | |
| JP6578323B2 (ja) | フィラグリン産生促進剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20120731 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20131225 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140107 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140407 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140414 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140507 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140514 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140606 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20150126 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150526 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20150629 |
|
| A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20150807 |